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Summary
An evaluation of a 38-year-old Caucasian woman, who 
was referred to Tygerberg Hospital (Western Cape 
Province, RSA) with Wenckebach second-degree or 
possibly complete atrioventricular (AV) block that had 
progressed from first-degree AV block, identified a fam-
ily history of the cardiac conduction system disorder 
progressive familial heart block type II (PFHBII). This 
prompted a retrospective clinical review of the subjects 
described in the original study, as well as additional 
family members who had not been examined in the 
original study.1 Progression of clinical features was 
observed, but more importantly, PFHBII was clinically 
redefined as an AV nodal disorder, which may progress 
to dilated cardiomyopathy (DCM). 
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In January 2003, a 38-year-old Caucasian woman with 
Wenckebach second-degree or possibly complete atrioven-
tricular (AV) block and a heart rate of 43 beats per minute 
(bpm) (Fig. 1) (Table I, individual IV:20) was admitted to 
the Cardiology Unit of Tygerberg Hospital (Western Cape 
Province). The subject had been examined previously (P.A. 
Brink, May 2000) and diagnosed with first-degree AV block 
with a P–R interval of 240 milliseconds (Fig. 2). Genealogy 
studies indicated that the subject was the daughter of the 
index case of the previously described South African family 
with progressive familial heart block type II (PFHBII).1
In 1977, Brink and Torrington characterised PFHBII as 
an inherited autosomal dominant cardiac conduction system 
disorder, which segregated in a South African Caucasian 
Afrikaner family from the Eastern Cape Province.1 The ECG 
features of PFHBII were at that time defined by isolated 
sinus bradycardia (SB), isolated left posterior hemiblock 
(LPHB) or complete heart block (CHB) with narrow QRS 
complexes. In this report, we describe a retrospective study 
of the family members examined by Brink and Torrington in 
1977. Clinical data are also presented of additional subjects 
from the same family who were not examined in the original 
study. The results of the study reiterated the progressive 
nature of the disorder and prompted a redefinition of the 
clinical profile of PFHBII.
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Fig. 1. Twelve-lead ECG strip for individual IV:20, 
taken in January 2003, showing a slow, irregular 
sinus rhythm with no consistent ventricular 
response. The AV nodal delay could represent a 
Wenckebach phenomenon or alternately, complete 
AV dissociation. The subject subsequently had a 
pacemaker implanted. 
Fig. 2. Twelve-lead ECG strip for individual IV:20, 
showing first-degree AV block (P–R interval = 240 
milliseconds). The ECG was taken in May 2000.
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Methods
Ethical approval
The present study formed part of a project approved by the 
Ethics Committee of the Faculty of Health Sciences at the 
University of Stellenbosch. 
Genealogy and extent of the disease
The South African Caucasian Afrikaner family presented in 
this study was previously described.1 Extensive genealogy 
studies were performed to determine the segregation of 
PFHBII in other branches of the family.
Patient panel
Twelve-lead ECG and two-dimensional echocardiographic 
follow-up examinations were acquired (1977 to present) 
from Tygerberg Hospital or from the personal physicians of 
subjects described in the original PFHBII study.1 Clinical 
data were also obtained for the children (born after 1977) of 
these subjects, as well as other available members who were 
not examined in the original study.1 Where the records were 
unavailable, if possible, clinical histories were obtained 
from the subjects themselves or close relatives. Clinical 
histories of deceased individuals were also included in the 
study.
Electrocardiographic and echocardiographic 
criteria
The ECG diagnostic criteria for PFHBII were previously 
established.1 In addition, the study included minimum 
criteria for an echocardiographic diagnosis of dilated 
cardiomyopathy (DCM), defined by an ejection fraction of 
less than 45% and a left ventricular end-diastolic diameter 
of greater than 5.6 cm in the absence of hypertension 
and valvular heart disease or a history consistent with 
ischaemic heart disease. All measurements were made 
according to the American Society of Echocardiography 
guidelines.2
Results
Genealogy and extent of the disease
The study by Brink and Torrington in 1977 obtained 
information on 140 members of a South African family, of 
which 24 members of one family branch were examined 
by ECG. We performed extensive family studies question-
ing living first-, second- and third-degree relatives of indi-
vidual II:2 (Fig. 3) (not including his progeny). Wherever 
possible, ECGs were performed, and occasionally echo-
cardiographic assessment. We did not detect disease with 
features of PFHBII, although one third-degree relative had 
hypertrophic cardiomyopathy. Additionally, we questioned 
relatives of individual II:3 (Fig. 3) and did not identify 
evidence of the disease in her lineage. We concluded that 
individual II:2 was the true carrier of PFHBII (Fig. 3), as 
his children reported him to have had a heart block. We do 
not therefore have evidence of segregation of the disease 
in ancestors or siblings and their progeny of II:2 and II:3, 
limiting known disease to the current pedigree (Fig. 3). 
TABLE I. EVALUATION OF FOLLOW-UP CLINICAL DATA OF THE PFHBII FAMILY MEMBERS 
CLINICALLY ASSESSED IN THE ORIGINAL STUDY
Indidual  aAge (y) ECG  EF LVEDD Comment
III:6 68 normal 76 4.8 unaffected
III:8 42 3° AVB 60 4.5 bSB = 48 bpm, CHB (PM 42 y); present age = 69 y
III:10 64 normal 65 4.4 unaffected 
III:12 37 3° AVB 41 6.3 CHB (PM 37 y), DCM, +59 y 
IV:9 41 3° AVB 42 5.7 CHB (PM 41 y), DCM, +46 y 
IV:11 35 3° AVB nd nd CHB (PM 35 y); present age = 36 y 
IV:14 32 normal 65 4.3 unaffected
cIV:16 40 normal 64 4.5  slow R-wave progression; transition to dominant R-wave in V4 – 
otherwise unaffected
IV:18 33 normal 70 4.7 unaffected
IV:19 31 normal 63 4.9 unaffected
IV:20 38 2° or 3° AVB 61 5.5  1° AVB (P–R interval = 240 m/s, May 2000); SB = 43 bpm, 
Wenckebach/complete AVB (PM 38 y), January 2003; present 
age = 38 y 
IV:21 41 normal 64 4.4 unaffected
IV:24 39 normal 60 4.5 unaffected
IV:25 29 3° AVB 40 5.8 CHB (PM 29 y), DCM, +43 y
IV:26 15 nd nd nd heart transplant, DCM, +15 y 
Not shown in the table are individuals II:3, III:7, III:9, III:11; IV:12, IV:13, IV:15, IV:17 and IV:22, who were designated 
clinically unaffected based on family history or a family physician’s medical report. No further data could be obtained for 
these individuals.
aAge at examination in years (y); bHeart rate prior to pacemaker (PM) implant; cIndividuals with atypical accompanying features; 
+Age at death
1° = first-degree; 2° = second-degree; 3° = third-degree; AVB = atrioventricular block; bpm = beats per minute; CHB = complete 
heart block; DCM = dilated cardiomyopathy; EF = ejection fraction; LVEDD = left ventricular end diastolic diameter; m/s = 
milliseconds; nd = no data available; (PM y) = PM age at implant; SB = sinus bradycardia 
Clinically affected individuals are indicated in bold
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Clinical data
Twenty-four subjects were assessed in the original study,1 
of whom six were designated clinically affected, and three 
were identified with SB. Follow-up clinical data or family 
histories were obtained for the 24 subjects described in 
the original study1 (Table I). Our data indicated that two 
of the three subjects previously identified with SB1 (Fig. 
3, individuals IV:9 and IV:20) subsequently developed AV 
block and had pacemakers implanted (Table I). Furthermore, 
three subjects (Fig. 3, individuals III:12, IV:9 and IV:25) 
showed progression to DCM (Table I). A fourth subject 
(Fig. 3, individual IV:26), who had previously shown no 
conduction abnormalities,1 required a heart transplant as a 
result of juvenile-onset DCM (Table I). Our follow-up data 
also differed from the previous diagnoses of three family 
members. These subjects (Fig. 3, individuals IV:16, IV:19 
and IV:24), who had previously been designated clinically 
affected, presently did not meet our strict diagnostic criteria, 
although individual IV:16 did present atypical associated 
features on examination (Table I). 
In addition, we obtained clinical or family information 
for 15 subjects who were not clinically examined in the 
original study or who were born after 1977 (Fig. 3). Eight 
of the 15 subjects were assigned a clinically affected status 
(Table II). Seven of the eight clinically affected individuals 
developed conduction defects that ranged from atrial fibril-
lation and CHB to left anterior hemiblock (LAH) (Table 
II). The eighth affected subject (Table II, individual IV:2) 
showed progression from AV block to DCM. An additional 
family member (Table II, individual V:1) presented with 
atypical features that included severe chest pain with 
frequent dyspnoea and syncopal episodes. However, the 
subject has declined to be examined and her clinical status 
remains uncertain.
Discussion
Evaluation of clinical and family data spanning 26 years 
confirmed the progression of features in PFHBII. More 
importantly, the study highlighted the progression to DCM, 
which was not apparent in the original study. The follow-up 
study showed that SB preceding CHB occurred frequently 
in the family, although it must be noted that SB is fairly 
common in the general population, particularly among 
athletes.3 However, upon questioning, most of the affected 
family members indicated that they had fairly sedentary 
lifestyles and SB was absent in unaffected subjects with 
similar living patterns. Therefore, in this family, a slow 
heart rate of less than 50 bpm is considered familial and a 
diagnostic criterion of PFHBII. 
Generally, individuals with first-degree AV block are 
asymptomatic and diagnosis thereof is usually incidental. 
The present study also aimed to identify clinical or physical 
characteristics occurring in the family that could be indica-
tive of underlying disease. Two subjects with potentially 
early clinical markers for PFHBII were identified. The 
first subject (individual IV:16), who was examined in the 
original study and re-evaluated by us in 2000, was, unlike 
the previous study, assigned a clinically unaffected status. 
Our evaluation did indicate a slow R-wave progression, 
where the transition to a dominant R-wave occurs in V4. 
A slow R-wave progression is often associated with DCM,4 
although lead placement could also play a role in the ECG 
assessment. However, we speculate that in this family, the 
atypical feature could be an early indication of impending 
Fig. 3. A family tree showing all kindred of an individual with PFHBII. Squares represent males and 
circles represent females. An asterisk indicates the individuals examined in the original study. The 
clinical assessments of subjects whose present diagnoses differ from the original study1 are shown 
below the respective symbols (af, subject previously diagnosed as affected; sb, subject previously with 
sinus bradycardia; unaf, subject previously unaffected).
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cardiac abnormalities. The second subject (individual V:1) 
had reported severe chest pains, shortness of breath and 
fainting episodes. Recent correspondence with individual 
V:1 indicated a persistence of features, despite treatment with 
Atenolol (P.A. Brink, personal communication). Interestingly, 
there is a history of sudden death at a relatively young age 
in the subject’s family, with both her grandfather and father 
(Table II, individuals III:1 and IV:2) having died aged 41 
and 43 years, respectively.  
The importance of this retrospective study is exemplified 
by our redefinition of the clinical profile of PFHBII. Barring 
the one individual with LAH (individual IV:1), we propose 
that the absence of ventricular conduction delay makes 
it highly likely that the conduction block occurs close to 
the origins of the Bundle of His. This suggests that PFHBII 
is not a disease of the ventricular conduction system. 
Drawing on observations from ECG data, we have amended 
the diagnostic criteria and characterise PFHBII as an 
AV nodal disorder with clinical onset between the fourth 
and sixth decade. In addition, four family members were 
identified who progressed from conduction block to DCM 
(Tables I and II, individuals III:12, IV:2, IV:9 and IV:25). 
For these subjects, the progression from complete AV block 
to congestive heart failure (CHF) ranged from five years 
(individuals IV:2 and IV:9) to 22 and 14 years (individual 
III:12 and IV:25), respectively. Furthermore, a fifth subject 
(Table I, individual IV:26) with no prior conduction defects 
developed DCM in early adolescence. Consequently, these 
data indicate that in this family, on average, death as a result 
of CHF occurred before the sixth decade. Unfortunately, 
the available data did not permit assessing whether the 
prognosis for individuals who only developed conduction 
defects was better than for those subjects with DCM. 
We cannot explain why particular individuals advanced 
from AV block to DCM, while others only developed 
conduction defects, but this pattern of clinical features was 
consistent with other described disorders.5,6 Consequently, 
we performed a genetic linkage study and excluded the 
lamin A/C5 and CMD1H6 loci as cause of PFHBII (data 
not shown). 
Conclusions
The data presented emphasise the importance of establish-
ing a family history when making patient diagnoses. The 
progressive nature of the disorder was reiterated, but more 
importantly, a familial DCM component was demonstrated 
in PFHBII. Consequently, the study provides a more com-
prehensive clinical profile of PFHBII, which may assist 
clinicians to identify other South African families or indi-
viduals with this potentially life-threatening disorder.
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TABLE II. EVALUATION OF CLINICAL DATA OF PFHBII FAMILY MEMBERS WHO WERE NOT 
CLINICALLY ASSESSED IN THE ORIGINAL STUDY
Indidual  aAge (y) ECG  EF LVEDD Comment
II:2 61 nd nd nd HB (type unknown), +61 y 
III:1 40 nd nd nd HR < 50 bpm, CHB (PM 41 y), +41 y 
III:3 45 nd nd  nd CHB (PM 45 y), failed PM, +45 y 
IV:1 36 LAD 64 4.4 LAD (–30º axis), LAH; present age = 41 y
IV:2 38 3° AVB 38 6.2 bSB = 50 bpm, AF, CHB (PM 39 y), DCM, +43 y
IV:4 49 normal 60 4.4 unaffected 
IV:5 45 normal 60 4.4 unaffected
IV:6 47 normal 65 4.5 unaffected 
IV:7 33 3° AVB 52 5.1  1° AVB (P–R interval = 220 m/s, March 1990),  cSB = 38 bpm, 
AF, CHB (PM 33 y, October 1996); present age = 38 y
IV:8 45 normal 65 4.8 unaffected 
IV:10 36 SB nd nd SB = 43 bpm; present age = 39 y
IV:23 16 3° AVB nd nd CHB (PM 16y), +16 y
cV:1 23 nd nd nd chest pain, dyspnoea, syncope 
V:3 22 160 63 5.2 unaffected
V:4 20 160 70 4.3 unaffected
aAge at examination in years (y); bHeart rate prior to pacemaker (PM) implant; cIndividuals with atypical accompanying features; 
+Age at death
1° = first-degree; 3° = third-degree; AF = atrial fibrillation; AVB = atrioventricular block; bpm = beats per minute; CHB = complete 
heart block; DCM = dilated cardiomyopathy; LVEDD = left ventricular end diastolic diameter; HB = heart block; HR = heart rate; 
LAH = left anterior hemiblock; LAD = left axis deviation; EF = ejection fraction; m/s = milliseconds; nd = no data available; 
(PM y) = PM age at implant; SB = sinus bradycardia
Clinically affected individuals are indicated in bold
